744-80-9CCC1(c2ccccc2)C(=O)NC(=O)N(C(=O)c2ccccc2)C1=OQMOWPJIFTHVQMB-UHFFFAOYSA-Nfor drug therapy of epilepsy
744-80-9DTXSID1046138CHEMBL1338506Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Drugs used to prevent SEIZURES or reduce their severity.
Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military.
Usesis used in preparation method and composition for treating epilepsy including administering a Cholecystokinin-2 receptor antagonist and combination with antiepileptic agents.
No reaction records under the current filter.
Loading…